SCHEDULE: Rosalind Funds Maintain ~10% Stake in Myomo, Inc.

Rosalind Advisors and Master Fund confirm a passive beneficial ownership of approximately 9.99% in Myomo, Inc., primarily through common stock and pre-funded warrants subject to blocker provisions.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively reported beneficial ownership in Myomo, Inc.
• The reporting persons beneficially own 3,839,772 shares of Myomo, Inc. common stock, representing approximately 9.99% of the outstanding class.
• This ownership percentage is based on 38,435,524 shares of common stock outstanding as of November 3rd, 2025, as reported in Myomo's 10Q filed on November 10th, 2025.
• An additional 3,763,258 shares of common stock are issuable upon exercise of pre-funded warrants, but these are subject to blocker provisions.
• The blocker provisions prevent the holder from exercising warrants to the extent that such exercise would result in beneficial ownership exceeding 9.99% of the Common Stock.
• Consequently, the reporting persons were unable to exercise any of the warrants as of the event date due to these blockers.
• Rosalind Advisors, Inc. acts as the investment advisor to Rosalind Master Fund L.P., and Steven Salamon is the portfolio manager of the Advisor.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as mildly positive to neutral. The continued significant, albeit passive, investment by Rosalind funds suggests a degree of confidence, while the clarification of blocker provisions provides transparency without indicating any immediate negative developments.

Positives

• A significant institutional investor group maintains a substantial, albeit passive, stake in Myomo, Inc., indicating continued interest.
• The filing clarifies the ownership structure, providing transparency regarding the investor's position.

Negatives

• The blocker provisions on pre-funded warrants limit the immediate exercisability of a significant portion of the potential ownership, preventing the investor from increasing their direct stake beyond 9.99% at this time.

Risks

• The existence of blocker provisions on pre-funded warrants means that a substantial portion of potential shares cannot be converted into common stock, which could impact future liquidity or strategic options for the warrant holders.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Myomo, Inc. It primarily details the current beneficial ownership of a passive investor group.

Industry Context

StockSavvy.ai notes that Schedule 13G/A filings are routine updates for passive investors holding significant stakes. The clarification of beneficial ownership, particularly regarding blocker provisions, is important for understanding the true voting power and potential influence of large shareholders in the medical technology sector, where Myomo operates. This filing indicates a stable, passive investment rather than an activist position.

Comparison to Industry Standards

• This filing is an ownership disclosure and does not contain operational or financial results that can be directly compared to industry benchmarks or specific competitor projects like ReWalk Robotics or Ekso Bionics. It focuses solely on the beneficial ownership structure of a specific investor group.

Stakeholder Impact

• Shareholders: Provides clarity on the beneficial ownership structure of a significant investor, confirming a passive stake and the limitations imposed by blocker provisions on warrant exercise.

Key Dates

Keywords

Myomo Inc., Rosalind Advisors, Rosalind Master Fund, Beneficial Ownership, Schedule 13G/A, Common Stock, Pre-funded Warrants, Blocker Provisions, Institutional Investor, Passive Investment